The risk for death was higher than the risk for kidney failure until patients reached eGFRs less than 45 mL/min/1.73m2. When it comes to competing risks in patients with diabetes and chronic kidney ...
Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.
Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with obesity and heart failure with preserved pump function, new research reveals. Weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results